Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of AZD1722 on Midazolam PK in Healthy Volunteers
NCT02140268Phase 1Completed
- Sponsor
- Ardelyx
- Start
- May 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tenapanor in irritable bowel syndrome (IBS) and hyperphosphatemia, sponsored by Ardelyx. Primary endpoints: Area Under the Concentration-Time Curve of Midazolam at Day 15 and Maximal Plasma Concentration of Midazolam at Day 15. Started May 2014; status: completed.
02
Drugs
tenapanor
03
Conditions
irritable bowel syndrome (IBS)hyperphosphatemia
Beyond the preview
Go deeper on NCT02140268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02140268.